COVID-19.рф: ИНФОРМАЦИЯ ПРОТИВ ПАНДЕМИИ

Поиск по репозиторию

Статья

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

B. Bikdeli, M. Madhavan, D. Jimenez, T. Chuich, I. Dreyfus, E. Driggin, C. Nigoghossian, W. Ageno, M. Madjid, Y. Guo, L. Tang, Y. Hu, J. Giri, M. Cushman, I. Quéré, E. Dimakakos, C. Gibson, G. Lippi, E. Favaloro, J. Fareed, J. Caprini, A. Tafur, J. Burton, D. Francese, E. Wang, A. Falanga, C. McLintock, B. Hunt, A. Spyropoulos, G. Barnes, J. Eikelboom, I. Weinberg, S. Schulman, M. Carrier, G. Piazza, J. Beckman, P. Steg, G. Stone, S. Rosenkranz, S. Goldhaber, S. Parikh, M. Monreal, H. Krumholz, S. Konstantinides, J. Weitz, G. Lip, C. Global, b. Endorsed, NATF, ESVM, t. and, b. Supported,
2021
https://doi.org/10.1016/j.jacc.2020.04.031

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic. © 2020 American College of Cardiology Foundation

Цитирование

Похожие публикации

Bridging the state-of-the-art and the state-of-the-practice of SaaS pricing: A multivocal literature review
A. Saltan, K. Smolander,
Specific influenza therapy: Current state and prospects (review)
A. Odnovorov, T. Grebennikova, T. Pleteneva,
Termination of pregnancy and follow-up contraception. What is important to consider in the current environment
E. Andreeva, Y. Absatarova,

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • B. Bikdeli
    NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, United States
  • M. Madhavan
    Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT, United States
  • D. Jimenez
    Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, United States
  • T. Chuich
    Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
  • I. Dreyfus
    Department of Medicine and Surgery, University of Insubria, Varese, Italy
  • E. Driggin
    McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States
  • C. Nigoghossian
    Department of Cardiology, Chinese PLA General Hospital, Beijing, China
  • W. Ageno
    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • M. Madjid
    Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
  • Y. Guo
    Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States
  • L. Tang
    Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States
  • Y. Hu
    University of Vermont Medical Center, Burlington, VT, United States
  • J. Giri
    Department of Vascular Medicine, University of Montpellier, Centre Hospitalier Universitaire Montpellier, InnoVTE F-CRIN Network, Montpellier, France
  • M. Cushman
    Oncology Unit GPP, Sotiria General Hospital Athens School of Medicine, Athens, Greece
  • I. Quéré
    Harvard Medical School, Boston, MA, United States
  • E. Dimakakos
    Beth Israel Deaconess Medical Center, Boston, MA, United States
  • C. Gibson
    Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy
  • G. Lippi
    Haematology Laboratory, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia
  • E. Favaloro
    Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia
  • J. Fareed
    Loyola University Medical Center, Chicago, IL, United States
  • J. Caprini
    Pritzker School of Medicine, University of Chicago, Chicago, IL, United States
  • A. Tafur
    Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, IL, United States
  • J. Burton
    Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy
  • D. Francese
    Auckland City Hospital, Auckland, New Zealand
  • E. Wang
    St Thomas’ Hospital, London, United Kingdom
  • A. Falanga
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, United States
  • C. McLintock
    Center for Bioethics and Social Science in Medicine, University of Michigan, Ann Arbor, MI, United States
  • B. Hunt
    Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States
  • A. Spyropoulos
    Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
  • G. Barnes
    Massachusetts General Hospital, Boston, MA, United States
  • J. Eikelboom
    Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
  • I. Weinberg
    McMaster University, Hamilton, Ontario, Canada
  • S. Schulman
    Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
  • M. Carrier
    Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  • G. Piazza
    Brigham and Women's Hospital, Boston, MA, United States
  • J. Beckman
    Vanderbilt University School of Medicine, Nashville, TN, United States
  • P. Steg
    INSERM U1148, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, FACT (French Alliance for Cardiovascular Trials), Paris, France
  • G. Stone
    Université Paris, Paris, France
  • S. Rosenkranz
    Royal Brompton Hospital, Imperial College London, London, United Kingdom
  • S. Goldhaber
    Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
  • S. Parikh
    Cologne Cardiovascular Research Center, Heart Center, Department of Cardiology, University of Cologne, Cologne, Germany
  • M. Monreal
    Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain
  • H. Krumholz
    Department of Health Policy and Administration, Yale School of Public Health, New Haven, CT, United States
  • S. Konstantinides
    Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States
  • J. Weitz
    Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany
  • G. Lip
    Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom
  • C. Global
    Aalborg University, Aalborg, Denmark
  • b. Endorsed
  • NATF
  • ESVM
  • t. and
  • b. Supported
Название журнала
  • Journal of the American College of Cardiology
Том
  • 75
Выпуск
  • 23
Страницы
  • 2950-2973
Ключевые слова
  • anticoagulant agent; antithrombocytic agent; antivitamin K; azithromycin; chloroquine; heparin; hydroxychloroquine; interferon; lopinavir plus ritonavir; low molecular weight heparin; methylprednisolone; remdesivir; sarilumab; tocilizumab; acute coronary syndrome; artery thrombosis; coronavirus disease 2019; critical illness; disease transmission; follow up; health care organization; health care personnel; health care system; heart muscle injury; hematological parameters; hemostasis; human; incidence; infection risk; pandemic; pathogenesis; priority journal; public health; Review; Severe acute respiratory syndrome coronavirus 2; thromboembolism; vein thrombosis; venous thromboembolism; virus transmission
Издатель
  • Elsevier USA
Тип документа
  • Review
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus
COVID-19.рф: Информация против пандемии

Адрес: 115114, Москва, ул. Летниковская, д. 4, стр.5, офис 2.4
тел.\факс: +7(499)754-99-94, доб. 502
e-mail: covid19@neicon.ru

Проект реализуется с использованием гранта Президента Российской Федерации на развитие гражданского общества, предоставленного Фондом президентских грантов.

Содержимое сайта, если не указано иное, опубликовано в соответствии с лицензией Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная (CC BY 4.0). Права на материалы, переданные партнерами проекта, принадлежат их правообладателям.

© 2025 NEICON